research use only
Cat.No.P1108
Amino-acid Sequence
CAS No. 1607799-13-2
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Storage (From the date of receipt) | 3 years-20°C powder | ||
|
In vitro |
DMSO
: 100 mg/mL
(92.14 mM);
Water : 100 mg/mL Ethanol : 100 mg/mL |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
| Description | Bremelanotide Acetate (PT-141 Acetate) is a melanocortin receptor (MCR) agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty. |
|---|
In Vivo |
||
| In vivo |
Bremelanotide, an analogue of the naturally occurring peptide a-MSH, activates the medial preoptic area (mPOA) and other hypothalamic and limbic regions of the brain involved in sexual behavior, and may work by activating dopamine terminals in the mPOA. |
|
|---|---|---|
| Animal Research | Animal Models | rat model of sexual desire |
| Dosages | 5, 100, 200, 800 μg/kg | |
| Administration | s.c. | |
References |
|
| Molecular Formula | C50H68N14O10.C2H4O2 |
|---|---|
| Molecular Weight | 1085.22 |
| CAS No. | 1607799-13-2 |
| Appearance | White Powder |
| Peptide Content (by %N) | ≥80% |
| Single Impurity (by HPLC) | ≤1.0% |
| Assay (By Anhydrous, Acetic Acid-free) | 95.0~105.0% |
| MS | Consistent |
| Packing | plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement. |
| Storage (From the date of receipt) |
3 years-20°C powder |
| Shipping | Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.) |